![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
New York, NY, and Tel Aviv, ISRAEL, Oct. 14, 2022 (GLOBE NEWSWIRE) — by way of NewMediaWire —Todos Medical, Ltd. (OTCQB: TOMDF), a complete medical diagnostics and associated options firm, as we speak introduced that its CLIA/CAP-certified medical laboratory Provista Diagnostics has filed an Emergency Use Authorization (EUA) software with the US Food & Drug Administration (FDA) for its PCR MonkeyPox Test. The EUA software was submitted for lesion-based PCR. The sensitivity achieved for the at present obtainable lesion-based laboratory-developed take a look at (LDT) is 0.95 viral copies per response (0.095 copies/ul).
“The submission of this EUA application underscores our commitment to providing best-in-class PCR-based testing for emerging infectious diseases,” mentioned Gerald E. Commissiong, President & CEO of Todos Medical and Provista. “Regulatory changes at FDA have forced us to only be able to offer lesion-based PCR testing. As we conduct more research and work with the agency, we are hopeful to be able to submit an EUA for saliva-based PCR testing for MonkeyPox in the future.”
About Todos Medical Ltd.
Founded in Rehovot, Israel with places of work in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic options for the early detection of quite a lot of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening know-how utilizing peripheral blood evaluation that examines most cancers’s affect on the immune system, in search of biochemical adjustments in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening checks, TMB-1 and TMB-2 have obtained a CE mark in Europe. Todos just lately acquired U.S.-based medical diagnostics firm Provista Diagnostics, Inc. to achieve rights to its Alpharetta, Georgia-based CLIA/CAP licensed lab at present performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast most cancers blood take a look at. More data on Provista is accessible at www.provistadx.com.
Todos can be creating blood checks for the early detection of neurodegenerative problems, equivalent to Alzheimer’s illness. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood take a look at that determines the flexibility of peripheral blood lymphocytes (PBLs) and monocytes to face up to an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that sure illnesses, most notably Alzheimer’s illness, are the results of compromised mobile equipment that results in aberrant cell cycle re-entry by neurons, which then results in apoptosis. LymPro is exclusive in using peripheral blood lymphocytes as a surrogate for neuronal cell perform, suggesting a standard relationship between PBLs and neurons within the mind.
Todos shaped the Israeli-based majority-owned three way partnership 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate the entire mental property surrounding 3CL protease–primarily based diagnostic testing and improvement of 3CL protease botanical and pharmaceutical inhibitors that concentrate on a basic reproductive mechanism of coronaviruses. 3CL Pharma, by Todos’ model, has commercialized the 3CL protease inhibitor immune assist dietary complement Tollovid™ within the United States, is creating the twin mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, whereas additionally creating the 3CL protease diagnostic TolloTest™.
To buy Tollovid please go to Amazon or www.MyTollovid.com. For extra data, please go to https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained on this press launch could represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated medical improvement packages and medical trials. These forward-looking statements are primarily based solely on present expectations of administration, and are topic to vital dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements, together with the dangers and uncertainties associated to the progress, timing, value, and outcomes of medical trials and product improvement packages; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology corporations; and our skill to acquire further funding required to conduct our analysis, improvement and commercialization actions. In addition, the next components, amongst others, might trigger precise outcomes to vary materially from these described within the forward-looking statements: adjustments in know-how and market necessities; delays or obstacles in launching our medical trials; adjustments in laws; incapacity to well timed develop and introduce new applied sciences, merchandise and purposes; lack of validation of our know-how as we progress additional and lack of acceptance of our strategies by the scientific neighborhood; incapacity to retain or appeal to key workers whose information is crucial to the event of our merchandise; unexpected scientific difficulties that will develop with our course of; higher value of ultimate product than anticipated; lack of market share and strain on pricing ensuing from the competitors; and laboratory outcomes that don’t translate to equally good ends in actual settings, all of which might trigger the precise outcomes or efficiency to vary materially from these contemplated in such forward-looking statements. Except as in any other case required by legislation, Todos Medical doesn’t undertake any obligation to publicly launch any revisions to those forward-looking statements to mirror occasions or circumstances after the date hereof or to mirror the incidence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please consult with its reviews filed occasionally with the U.S. Securities and Exchange Commission.
Todos Corporate Contact:
Daniel Hirsch CFO
Todos Medical
917-983-4229 x 104
[email protected]
Todos Press Contact:
Giancarlo Greager
TreviPR
702-768-1906
[email protected]
